Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Wang Z, Duan J, Wang G, Zhao J, Xu J, Han J, Zhao Z, Zhao J, Zhu B, Zhuo M, Sun J, Bai H, Wan R, Wang X, Fei K, Wang S, Zhao X, Zhang Y, Huang M, Huang D, Qi C, Gao C, Bai Y, Dong H, Xiong L, Tian Y, Wang D, Xu C, Wang W, Li J, Hu X, Cai S, Wang J.
Wang Z, et al. Among authors: cai s.
J Thorac Oncol. 2020 Apr;15(4):556-567. doi: 10.1016/j.jtho.2019.12.001. Epub 2019 Dec 12.
J Thorac Oncol. 2020.
PMID: 31843683
Free article.